Covishield leh Covaxin hmanpawlhin result ṭha zawk a siam : ICMR

Indian Council of Medical Research (ICMR) chuan India rama Covid-19 vaccine hman lar pahnih, Covishield leh Covaxin-te chu hman pawlh chuan result ṭha zawk a siam tih an sawi.

Uttar Pradesh-a tih palh thila vaccine chi hnih mi 18-te hnenah pek a nih hnuah he zirchianna hi neih a ni.

‘Serendipitous Covid-19 Vaccine-Mix in Uttar Pradesh, India: Safety and Immunogenicity Assessment of a Heterologous Regime’ tih hmanga zirchianna neihah hian vaccine chi hnih pek kawp mi 18 te taksa leh, Covishield dose hnih latu mi 40 leh Covaxin dose hnih latu mi 40-te chu zirchiangin khaikhin a ni. May leh June thla chhung khan zirchianna hi neih a ni.

Pune-a Serum Insitute of India siam, Covishield hi adenovirus vector platform-based vaccine niin, Bharat Biotech leh ICMR siam Covaxin hi whole virus vaccine a ni thung. "Natna kan do theihnan adenovirus vector platform-based vaccine zawhah inactivated whole virus vaccine lak hi a him mai ni loin taksaa kan natna do theihna te a tichak thei a ni" tiin zirchianna chuan a sawi.

Central Drugs Standard Control Organisation (CDSCO)-a Subject Expert Committee (SEC) te chuan zirchhianna in a tum ber chu mipakhat hnenah vaccine in ang lo kan pek theih leh theih loh enchhinna a nih thu a tarlang.